Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615843 | 0.91 | — | — | |
| SCHEMBL15164531 | 0.81 | NPC1 (0.37) | ALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL13615837 | 0.80 | — | — | |
| SCHEMBL15975774 | 0.78 | NPC1 (0.47) | ALDH1A1HPGDMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL14211432 | 0.77 | ALOX5 (0.33) | — | |
| SCHEMBL15164529 | 0.76 | ALDH1A1 (0.42) | ALDH1A1HPGDTSHRMAPK1CASP1 | |
| SCHEMBL21453543 | 0.74 | KDM4E (0.33) | ALDH1A1HPGD | |
| SCHEMBL27394474 | 0.74 | CYP1A2 (0.45) | ALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL17791407 | 0.73 | MEN1 (0.32) | L3MBTL1 | |
| SCHEMBL13615839 | 0.71 | SMN1; SMN2 (0.53) | ALDH1A1HPGDTSHRMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090273278-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090273278-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | ALDH1A1 92/4885HPGD 1011/4885TSHR 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.